114f98f38e9f42d99b8c4729335a73883a9707d4fffd4fc4adda816df541dba1648c3f011975428297a21e840f5479f97290a3b0b5c8457081703facdcbaae8e7471cd32f4e74115bb5db4ce843808c693906f02a0974630abfdc494fe425a61c90eeb5901ef421cad6bd0acb278fb6cdffc422800674c278664740f62083c50e7dddd441266471cb9a2418cfe5c3dc6e801eb7a2b264545adcbb0b2b0c9cd32
agent
Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independentlyFunctional neuroanatomy and neuropathology of the human hypothalamusEarly cytoskeletal changes as shown by Alz-50 are not accompanied by decreased neuronal activityArguments for and against the primary amyloid local induction hypothesis on the pathogenesis of Alzheimer's diseaseSomatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patientsCytoskeletal alterations in the hypothalamus during aging and in Alzheimer's disease are not necessarily a marker for impending cell deathReduced neuronal activity is one of the major hallmarks of Alzheimer's diseaseThe monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with somatostatinergic neurons in the normal human hypothalamus and adjoining areasThe distribution of Alz-50 immunoreactivity in the hypothalamus and adjoining areas of Alzheimer's disease patientsTau and ubiquitin in the human hypothalamus in aging and Alzheimer's disease
author
type
label
J.A.P. van de Nes
firstName
J.A.P. van de